Guilin Layn Natural Ingredients Corp (002166.SZ): Cumulative repurchase of 1.08% of shares.
Guilin Layn Natural Ingredients Corp. (002166.SZ) announced that as of August 31, 2024, the company has repurchased a total of 7,992,071 shares of the company through the stock repurchase special securities account through centralized bidding trading, accounting for 1.08% of the company's total share capital. The highest fill price was 7.00 yuan per share and the lowest fill price was 5.90 yuan per share, with a total fill amount of RMB 49,955,093.26 (excluding transaction fees).
RheinBio: 2024 Semi-Annual Report Summary
RheinBio: 2024 semi-annual report
Guilin Layn Natural Ingredients Corp. (002166.SZ): Net income in the first half of the year was 64.8931 million yuan, a year-on-year increase of 79.28%.
On August 28th, Guilin Layn Natural Ingredients Corp. (002166.SZ) announced its semi-annual report for 2024, with a revenue of 0.725 billion yuan, a year-on-year growth of 41.65%; a net income attributable to the shareholders of the listed company of 64.8931 million yuan, a year-on-year growth of 79.28%; a net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses of 65.3593 million yuan, a year-on-year growth of 1,548.95%; and an earnings per share of 0.09 yuan.
guilin layn natural ingredients corp. (002166.SZ) released its performance for the first half of the year, with a net income of 64.893 million yuan, a year-on-year increase of 79.28%.
Guilin Layn Natural Ingredients Corp. (002166.SZ) released its semi-annual report for 2024, with a revenue of 0.725 billion yuan, a year-on-year...
Guilin Layn Natural Ingredients Corp.: 2024 Interim Performance Forecast
Guilin Layn Natural Ingredients Corp. (002166.SZ): Net income in the first half of the year is expected to increase by 50%-80%.
On July 8th, Geelong announced the performance forecast for the first half of 2024 for Guilin Layn Natural Ingredients Corp. (002166.SZ), with a net income attributable to shareholders of the listed company of RMB 54.2946 million to RMB 65.1536 million, an increase of 50% to 80% compared with the same period last year; the net income after deducting non-recurring gains and losses is RMB 45.2546 million to RMB 56.1136 million, an increase of 1041.73% to 1315.69% compared with the same period last year; and the basic earnings per share are RMB 0.0732 to RMB 0.0878. During the reporting period, the company continued to operate in the plant extract industry.
Guilin Layn Natural Ingredients Corp. (002166.SZ): It is expected that the gross margin of the company's entire business scope will remain in the range of 25-30% this year.
Guilin Layn Natural Ingredients Corp. (002166.SZ) stated on the investor platform that the gross margin of the company's natural sweetener products declined in 2023, but gradually improved since the fourth quarter of last year, and has been significantly improved in the first quarter of 2024, increasing by nearly 5 percentage points compared to 2023. It is expected that the gross margin of the company's overall business this year will remain in the range of 25-30%.
Guilin Layn Natural Ingredients Corp. (002166.SZ) plans to reduce its shareholding by no more than 0.94% for some of its directors and executives.
Guilin Layn Natural Ingredients Corp. (002166.SZ) announced that Mr. Yao Xinde, director of the board, and Mr. Xie Yongfu, director and executive vice president, Mr. Bai Yu, director and deputy general manager, Mr. Luo Huayang, deputy general manager and secretary of the board of directors, and Ms. Zheng Hui, CFO (hereinafter referred to as "above personnel") plan to reduce their holdings of part of the company's shares by means of centralized bidding and bulk trading within 3 months after 15 trading days from the day when this announcement is disclosed (from July 2, 2024 to September 30, 2024). The total number of shares to be reduced this time does not exceed 6.8952 million shares.
Does Guilin Layn Natural Ingredients (SZSE:002166) Have A Healthy Balance Sheet?
RheinBio (002166.SZ): 2023 equity distribution 10 distribution of 2 yuan share registration date May 31
On May 24, GLONGHUI (002166.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 2.000000 in cash (tax included) to all shareholders for every 10 shares based on 733,994,754.00 shares after excluding 7,992,071.00 shares of the company's existing total share capital. The share registration date for this equity distribution is May 31, 2024; the exclusive dividend date is June 3, 2024.
Why Guilin Layn Natural Ingredients' (SZSE:002166) Shaky Earnings Are Just The Beginning Of Its Problems
The Price Is Right For Guilin Layn Natural Ingredients Corp. (SZSE:002166)
RheinBio (002166.SZ): The overall gross margin for the whole year is expected to remain within a relatively reasonable margin of 25-30%
Gelonghui, April 29丨RheinBio (002166.SZ) held an online exchange on April 26, 2024 to discuss “Based on the first quarter results, does the company have performance guidelines for the full year 2024?” The company replied that in terms of revenue, we will continue to maintain a 15% -20 growth forecast after considering possible quarterly performance fluctuations. In terms of profit, judging by the gross margin level in the first quarter and the price trend of raw materials this year, the overall gross margin for the whole year is expected to remain within a relatively reasonable margin range of 25-30%.
Rheinbio (002166.SZ): Currently, the construction of the synthetic biology plant has entered a relatively advanced stage, and it is expected to be put into use in the third quarter
Gelonghui April 29 丨 Rheinland Biotech (002166.SZ) held an online exchange on April 26, 2024, about “What are the company's latest developments in the synthetic biology business?” The company replied that the construction of the synthetic biology plant has now entered a relatively advanced stage and is expected to be put into use in the third quarter. In terms of research and development, R&D projects for full synthesis and enzymatic transformation technology are progressing normally, and phased results have been achieved. In particular, projects to produce some high-value natural sweetener ingredients through enzymatic conversion technology have passed pilot tests, and can be quickly put into production after the factory is completed.
RheinBio (002166.SZ): Net profit of 267.901 million yuan in the first quarter increased by 34.37% year-on-year
Gelonghui, April 26 | Rhine Biotech (002166.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 341 million yuan, up 35.07% year on year; net profit attributable to shareholders of listed companies was 267.91 million yuan, up 34.37% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 395.709 million yuan, up 372.05% year on year; basic earnings per share were 0.04 yuan.
RheinBio (002166.SZ): The company has not cooperated with cannabis production and processing companies
Gelonghui, April 18 | Rhine Biotech (002166.SZ) said on the investor interactive platform that the company has not yet cooperated with cannabis production and processing companies.
RheinBio (002166.SZ): The company's industrial hemp factory mainly produces CBD and derivatives and other related products
Gelonghui, April 18 | Rhine Biotech (002166.SZ) said on the investor interactive platform that the company's industrial hemp factory mainly produces CBD and related products such as derivatives.
RheinBio (002166.SZ): Expected revenue growth rate of 15%-20% for the full year of 2024
Gelonghui, April 17, 丨 Rhine Biotech (002166.SZ) held an online exchange on April 15, 2024. “According to the analysis of the company's previous financial data, 12% is the center of the company's net profit margin. I would like to ask how long the company's net profit is expected to recover to this level?” The company replied that according to the current business development situation, the company expects a revenue growth rate of 15% to 20% for the full year of 2024, and the net profit of the main business is expected to more than double. Although the company will have some changes in expenses this year, the commissioning of the new plant will lead to an increase in depreciation expenses for some fixed assets, as well as this year
Rhine Biotech (002166.SZ): It is expected that the amount of raw material grown in Luo Han Guo may decline in 2024
Gelonghui, April 17, 丨 Rhine Biotech (002166.SZ) held an online exchange on April 15, 2024, about “After experiencing last year's oversupply situation, how is the Luo Han Guo industry expected to change this year?” The company replied that it is expected that the amount grown on the raw material side of Luo Han Guo may decline in 2024, be partially reduced from 2023, and the purchase price has recovered. If it is transmitted, the market price of the extract is expected to rise accordingly. The company stated many times earlier that too low or too high raw material prices are not conducive to the long-term stable development of the plant extraction industry. What we are looking forward to is the raw material side
No Data